ArticleMolecular genetics & genomic medicine2026
Prenatal Exome Diagnostic Yield, Syndromic Landscape and Secondary Findings.
Article in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveExome sequencing (ES) has become increasingly more prevalent across maternal fetal medicine spaces when anomalies are visualized on ultrasound. As such, Prevention Genetics implemented secondary finding categories into their prenatal exome based on professional recommendations in June of 2021. This study aimed to determine the diagnostic yield and syndromic landscape of reported variants during that timeframe.
methodsPrenatal ES cases from June 2021 to June 2023 were retrospectively reviewed for secondary finding opt-ins, overall result outcomes, variant nomenclature, and inheritance/segregation patterns. From this data, quantitative and descriptive statistical methods were used to determine the frequency of positive primary and secondary results, including cases in which multiple molecular diagnoses were detected.
resultsOf 520 fetal samples included in the cohort, 131 (25.2%) had a positive molecular result consistent with the clinical indication for exome. Within those 131 cases, 81 (61.8%) were caused by a de novo variant. From the total 520-sample cohort, 260 (50%) cases opted into at least one SF category. Among the 222 fetuses tested in which ACMG guideline-recommended genes were opted into, 14 (6.3%) were found to carry a reportable variant in genes associated with cardiovascular, metabolic, pediatric tumor-predisposition, or connective-tissue disorders. Four fetuses in the COD opt-in cohort were discovered to carry a deleterious variant in two separate SF genes, constituting comorbid pediatric molecular diagnoses. Unlike the primary reporting category, the majority (N = 25/30, 83.3%) of COD SF variants were inherited from a carrier parent.
conclusionThe aim of this study is to provide meaningful information that can aid in the exome consenting process as improvements in testing technologies and laboratory offerings evolve in response to developments in genetic understanding and professional guidelines. As such, it is crucial for healthcare teams to stay abreast of the increased scope of testing, potential test outcomes, and the phenotypic expansion of various genetic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.